The New York Times once called John Lamattina, then Pfizer head of R&D, “Dr. Optimistic.” He’s not so optimistic now.

LANSING, Mich. (WLNS)— As the entire world continues to grasp the COVID-19 pandemic and find a cure, Pfizer one of the world’s leaders in a biopharmaceutical company has helped find a vaccine. The ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. NEW YORK — As the Pfizer COVID vaccine ...

More than a dozen states are now expecting far fewer doses of the Pfizer COVID-19 vaccine next week, with no explanation from the Trump administration for why the shipments have been cut. It’s still ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. SACRAMENTO, Calif. (KTXL) — Pfizer revealed ...

Pfizer could have data on how well its Covid-19 vaccine works in kids under age 5 by the end of the year, according to CEO Albert Bourla. "We have a study in children 6 months to 2 years and then ...

Pfizer's CEO says the company is submitting data to the Food and Drug Administration on the need for a fourth dose of its COVID-19 vaccine. While the shot Pfizer is currently producing with BioNTech ...

The following is a transcript of an interview with Pfizer CEO Dr. Albert Bourla that aired Sunday, September 13, 2020, on "Face the Nation." Bourla also appeared on "Face the Nation" on March 13, 2022 ...

Pfizer chairman Albert Bourla told Dateline host Lester Holt that the pharmaceutical company was “not certain” if the vaccine prevented the coronavirus from being transmitted, saying, “This is ...

Side effects that have emerged in a large late-stage trial of a Covid-19 vaccine candidate from Pfizer Inc. and BioNTech SE are in line with those seen in smaller early studies, a positive sign for ...

Every time Andrew publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...

Pfizer and BioNTech are confident they can have a vaccine against the novel coronavirus ready for regulatory approval by the middle of October or early November, BioNTech CEO and co-founder Ugur Sahin ...